Showing 3251-3260 of 8741 results for "".
- New Agreement Opens Premier Networks to TeleVox Techhttps://practicaldermatology.com/news/televox-and-premier-inc-announce-national-patient-engagement-agreement/2476115/TeleVox has announced a national group purchasing agreement with Premier, Inc. effective September 1, 2025, permiting Premier members to access negotiated pricing and terms for TeleVox offerings, including Digital Front Door, Appointment Management, Digital Care P
- New: Researchers ID Polygenic Signature in Sporadic HShttps://practicaldermatology.com/news/researchers-identify-polygenic-signature-in-sporadic-hs/2476099/Researchers on a new study proposed a polygenic score (PGS) model that points to a genetic contribution to susceptibility in sporadic hidradenitis suppurativa (spHS). Publishing in the Journal of Investigative Dermatology
- Case Study: Non-Invasive Combo Therapy Resolves Nodular BCChttps://practicaldermatology.com/news/case-study-non-invasive-combo-therapy-resolves-nodular-bcc/2476081/A combination of cryotherapy, 5-fluorouracil, and imiquimod achieved clinical resolution of a large nodular basal cell carcinoma (nBCC) in the inguinal region, according to a recent case report in the Journal of Clinical and Aest
- NPF and Boehringer Unite to Launch First GPP Awareness Dayhttps://practicaldermatology.com/news/NPF-Boehringer-Unite-Launch-First-GPP-Awareness-Day/2475890/Key Takeaways NPF and Boehringer Ingelheim launched a campaign to educate and support individuals with generalized pustular psoriasis.
- Analysis: New Biologics Account for 70% of Increased Medicare Dermatology Drug Spendinghttps://practicaldermatology.com/news/analysis-new-biologics-account-for-70-of-increased-medicare-dermatology-drug-spending/2475722/Spending on dermatology-related drugs under Medicare Part D nearly quadrupled between 2013 and 2022, with specialty medications (including biologics) responsible for the vast majority of that increase, according to a new study.
- OSkin Study: Genetic Risk and Nevus Count Stronger Predictors for NAMhttps://practicaldermatology.com/news/genetic-risk-and-nevus-count-stronger-predictors-for-nam-study-finds/2475635/High nevus density and polygenic susceptibility are more strongly associated with nevus-associated melanoma (NAM) than with de novo melanoma, according to results from a new large-scale, population-based cohort study. The QSk
- SKINVIVE sPMA Accepted for Neck Line Treatmenthttps://practicaldermatology.com/news/skinvive-spma-accepted-for-neck-line-treatment/2475452/The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental premarket approval (sPMA) application from Allergan Aesthetics, an AbbVie company, for SKINVIVE by JUVÉDERM® for the treatment of neck lines in adults, according to a press release.<
- New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025https://practicaldermatology.com/news/new-data-for-lebrikizumab-and-tildrakisumab-unveiled-at-icd-2025/2475320/New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.
- New Biomarkers Linked to Atopic Dermatitis Severityhttps://practicaldermatology.com/news/new-biomarkers-linked-to-atopic-dermatitis-severity/2475296/New data published in JID Innovations shows elevated levels of immune cells in patients with atopic dermatitis (AD).
- Aesthetic Management Partners Launches New Non-Surgical Skin Revitalization Systemhttps://practicaldermatology.com/news/aesthetic-management-partners-launches-new-non-surgical-skin-revitalization-system/2475272/Aesthetic Management Partners announced the launch of PLADUOpro, a dual argon and nitrogen gas plasma system designed for advanced skin restoration, earlier this month.